Selected Abstract: Asciminib provides long-term, durable molecular responses and a consistent safety profile in patients with T315I-mutated CML-CP with up to approximately 6 years' exposure: final analysis from a phase 1 trial
ESH eLearning, Jorge Cortes,
4145930